Last reviewed · How we verify

VBI Vaccines Inc. — Portfolio Competitive Intelligence Brief

VBI Vaccines Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sci-B-Vac-Lot A Sci-B-Vac-Lot A phase 3 Recombinant hepatitis B vaccine Hepatitis B surface antigen (HBsAg) Immunology / Infectious Disease
Sci-B-Vac-Lot B Sci-B-Vac-Lot B phase 3 vaccine Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Central Hospital, Nancy, France · 2 shared drug classes
  2. Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. Aeras · 1 shared drug class
  5. Alba Maria Ropero · 1 shared drug class
  6. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  7. Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
  8. Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for VBI Vaccines Inc.:

Cite this brief

Drug Landscape (2026). VBI Vaccines Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vbi-vaccines-inc. Accessed 2026-05-16.

Related